Combination Of Antigens From Multiple Viral Species (e.g., Multivalent Viral Vaccine, Etc.) Patents (Class 424/202.1)
-
Publication number: 20140220073Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: SANOFI PASTEUR SAInventors: Alain BOUCKENOOGHE, Remi FORRAT, Denis CREVAT
-
Publication number: 20140219954Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.Type: ApplicationFiled: March 17, 2014Publication date: August 7, 2014Inventor: Rudi Mueller-Walz
-
Patent number: 8790657Abstract: This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes.Type: GrantFiled: June 26, 2009Date of Patent: July 29, 2014Assignee: Biomune CompanyInventors: Kristi Mae Dorsey, John Knox Rosenberger, Sandra Cloud Rosenberger
-
Patent number: 8778355Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.Type: GrantFiled: February 1, 2012Date of Patent: July 15, 2014Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Knut Elbers, Christiane Fetzer, Martina von Freyburg, Gregor Meyers
-
Patent number: 8771704Abstract: The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions with endothelial cells and platelets, and is able to shorten the bleeding time.Type: GrantFiled: September 12, 2011Date of Patent: July 8, 2014Assignee: National Cheng Kung UniversityInventor: Yee-Shin Lin
-
Patent number: 8748127Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: June 10, 2014Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Publication number: 20140154284Abstract: Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.Type: ApplicationFiled: July 17, 2012Publication date: June 5, 2014Applicant: The United States of America,as represented by the Secretary Department of Health & Human ServicesInventors: Christopher B. Buck, Diana V. Pastrana
-
Publication number: 20140154265Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.Type: ApplicationFiled: September 24, 2013Publication date: June 5, 2014Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
-
Patent number: 8734808Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.Type: GrantFiled: October 14, 2010Date of Patent: May 27, 2014Assignee: The Board of Regents for Oklahoma State UniversityInventor: Sanjay Kapil
-
Publication number: 20140141040Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20140134202Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.Type: ApplicationFiled: December 13, 2011Publication date: May 15, 2014Applicant: FOLIA BIOTECH INC.Inventors: Denis LECLERC, Nathalie MAJEAU, Constantino Roberto LOPEZ-MACIAS, III, Alain LAMARRE
-
Patent number: 8715689Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.Type: GrantFiled: April 27, 2009Date of Patent: May 6, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Claire Y. H. Kinney, Eric Thomas Beck, Richard M. Kinney
-
Patent number: 8703480Abstract: Provided are novel vectors comprising virus or viral portions in which biological function is effected by components on the surface or envelope. Biological function includes viral nucleic acid propagation and delivery in the same vector as well as other important functions such as enhanced target cell specificity and other favorable properties for endocytosis, nuclear localization, integration into the target cell genome and enhanced transduction efficiency functions. Also provided by this invention are chimeric cells useful as packaging cell lines or as target cells or even as both. By virtue of their unique sequences, such chimeric cells provide the machinery for viral nucleic acid propagation and packaging combined with other useful properties for delivering genetic information to any target cells of interest. Also provided are other vectors including those comprising initial nucleic acid wherein the initial nucleic acid has been modified and novel reconstituted vectors and fused vectors.Type: GrantFiled: January 14, 1998Date of Patent: April 22, 2014Assignee: Enzo Therapeutics, Inc.Inventors: Dakai Liu, Elazar Rabbani
-
Patent number: 8697353Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.Type: GrantFiled: February 1, 2011Date of Patent: April 15, 2014Assignee: Sanofi Pasteur SAInventors: Alain Bouckenooghe, Remi Forrat, Denis Crevat
-
Patent number: 8691234Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.Type: GrantFiled: April 27, 2009Date of Patent: April 8, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
-
Patent number: 8691239Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 25, 2013Date of Patent: April 8, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20140093535Abstract: The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies.Type: ApplicationFiled: May 25, 2012Publication date: April 3, 2014Applicant: SINOVET (BEIJING) BIOTECHNOLOGY CO., LTDInventors: Hua Wu, Yanliang He, Mingqi Xia
-
Publication number: 20140079732Abstract: The present invention relates to the field of vaccines. More specifically the present invention relates to compositions and methods for enhancing immune responses induced by vaccines, including vaccines targeted at secondary infections and conditions associated with influenza infection.Type: ApplicationFiled: January 27, 2012Publication date: March 20, 2014Applicant: GAMMA VACCINES PTY LIMITEDInventors: Arno Mullbacher, Mohammed Alsharifi, Tim Hirst, Yoichi Furuya
-
Publication number: 20140079733Abstract: Provided herein are compositions comprising a canine influenza virus and a canine respiratory coronavirus. They can further comprise Bordetella bronchiseptica, pertactin, canine parainfluenza virus, and canine adenovirus serotype 2. The compositions are effective for treating or preventing canine respiratory diseases, including canine infectious respiratory disease complex.Type: ApplicationFiled: February 3, 2012Publication date: March 20, 2014Inventors: Omar Yousif Abdelmagid, Joseph Michael Bricker, Shelly Lynn Shields
-
Patent number: 8673316Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: August 18, 2011Date of Patent: March 18, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 8663653Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.Type: GrantFiled: July 24, 2009Date of Patent: March 4, 2014Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
-
Publication number: 20140056942Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.Type: ApplicationFiled: August 15, 2013Publication date: February 27, 2014Inventors: Zhisong Qiao, Kevin O'Connell
-
Publication number: 20140037680Abstract: This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants.Type: ApplicationFiled: March 15, 2013Publication date: February 6, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Ann-Muriel STEFF, Jean-Francios TOUSSAINT
-
Patent number: 8642258Abstract: The present invention relates to a product named “immunogenical complex”, which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of the antigens that compose it to lymphocytes, in a safe, gradual and extended way, which leads to a more efficient immunological memory, increases the immunogenicity of the antigen and improves the production of antibodies. This ensures an efficient immunological protection with fewer amounts of antigens and/or less repetitions of vaccinal doses. In addition, the characteristics of the immunogenical complex of the present invention promotes effective immunity induction, homogeneous in “god and bad respondent” individuals.Type: GrantFiled: September 12, 2006Date of Patent: February 4, 2014Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda., Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FapespInventors: Ogari Pacheco, Osvaldo Augusto Sant'Anna, Lucildes Mercure, Jivaldo Matos, Márcia Fantini
-
Patent number: 8637046Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: GrantFiled: October 1, 2009Date of Patent: January 28, 2014Assignees: Cornell University, Novartis AGInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Patent number: 8618275Abstract: The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a.Type: GrantFiled: May 19, 2008Date of Patent: December 31, 2013Assignee: Hvidovre HospitalInventors: Tanja Bertelsen Jensen, Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Publication number: 20130337007Abstract: The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.Type: ApplicationFiled: December 28, 2011Publication date: December 19, 2013Inventor: Stephane Villoing
-
Patent number: 8580270Abstract: The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV.Type: GrantFiled: September 30, 2009Date of Patent: November 12, 2013Assignee: University of MassachusettsInventor: Trudy G. Morrison
-
Publication number: 20130295165Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV).Type: ApplicationFiled: January 13, 2012Publication date: November 7, 2013Applicant: VARIATION BIOTECHNOLOGIES, INC.Inventors: David E. Anderson, Tanvir Ahmed, Jasminka Bozic, Marc Kirchmeier
-
Patent number: 8574593Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: December 7, 2012Date of Patent: November 5, 2013Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8569472Abstract: The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analysis.Type: GrantFiled: December 19, 2008Date of Patent: October 29, 2013Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
-
Publication number: 20130280293Abstract: The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, Haemophilius influenza, Hepatitis B, Corynebacterium diphtheriae, Clostridium tetani, Bordatella pertusis (acellular) in a single combined vaccine. The invention also provides for a bivalent immunogenic composition against rota virus and polio virus. The process of making such compositions of the multivalent antigens are also disclosed. The present invention also relates to the production and use of such vaccines for prophylaxis against the infections mentioned above.Type: ApplicationFiled: January 3, 2012Publication date: October 24, 2013Applicant: Bharat Biotech International LimitedInventors: Gopinathan Kuppuswamy, Vijayanand Thiagarajan
-
Publication number: 20130280294Abstract: Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, managing, and/or ameliorating a viral or microbial infection, or one or more symptoms thereof, including, for example, those infections giving rise to shipping fever, bovine respiratory disease complex, and/or bovine viral diarrhea, particularly in susceptible or infected animals.Type: ApplicationFiled: December 21, 2011Publication date: October 24, 2013Applicant: ELI LILLY AND COMPANYInventors: Dale Wade Weise, James Robert Harris
-
Patent number: 8563706Abstract: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis.Type: GrantFiled: December 19, 2008Date of Patent: October 22, 2013Assignee: Hvidovre HospitalInventors: Troels Kasper Hoyer Scheel, Judith M. Gottwein, Jannick Prento, Tanja Bertelsen Jensen, Jens Bukh
-
Patent number: 8535665Abstract: The present invention discloses a process for simple and rapid detection and identification of molecular mimicry or mimic antigens or molecules existing in/on humans, animals and plants. The molecular mimicry can be related to infections, autoimmune diseases, cancers, obesity and other disorders. Therefore, novel methods for the diagnosis, prevention, and treatment of infections, autoimmune diseases, cancers, obesity and other disorders obtainable based on these mimic antigens or molecules can be developed. Furthermore, the present invention also reveals a new functional mechanism of vaccine and passive immunity and novel vaccines obtainable based on the new mechanism.Type: GrantFiled: August 17, 2007Date of Patent: September 17, 2013Inventor: Huiru Wang
-
Patent number: 8529906Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.Type: GrantFiled: June 1, 2010Date of Patent: September 10, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Manmohan Singh
-
Patent number: 8524249Abstract: A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.Type: GrantFiled: December 15, 2010Date of Patent: September 3, 2013Assignees: University of Saskatchewan, University of GuelphInventors: Susantha Gomis, Suresh Kumar Tikoo, Davor Ojkic
-
Patent number: 8524461Abstract: A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides.Type: GrantFiled: March 4, 2010Date of Patent: September 3, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Marcia L. Kalish, Clement B. Ndongmo, Chou-Pong Pau, William M. Switzer, Thomas M. Folks
-
Patent number: 8518410Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: March 4, 2010Date of Patent: August 27, 2013Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
-
Patent number: 8512711Abstract: An isolated protein comprising a VP1 amino acid sequence wherein one or more exposed loops within said VP1 has an insertion of an amino acid sequence from a virus protein other than VP1, and encoding nucleic acid, are provided. Typically, the virus protein other than VP1 is derived from an influenza virus and in particular, avian influenza virus. The isolated protein may have an insertion of amino acid sequence from a single protein or a plurality of proteins. Also provided are expression constructs, VLPs, pharmaceutical compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of any disease of viral origin, and in particular, influenza virus.Type: GrantFiled: October 4, 2007Date of Patent: August 20, 2013Assignee: The University of QueenslandInventors: Linda Hwee-Lin Lua, Anton Peter Jacob Middelberg
-
Publication number: 20130209507Abstract: The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Applicant: MERIAL LIMITEDInventors: Russell F. Bey, Randy S. Simonson, Kamesh Reddy Sirigireddy, Benjamin Matthew Hause
-
Patent number: 8506969Abstract: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.Type: GrantFiled: July 31, 2009Date of Patent: August 13, 2013Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
-
Publication number: 20130202655Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.Type: ApplicationFiled: April 22, 2011Publication date: August 8, 2013Applicant: AKTIV-DRY LLCInventors: Robert E. Sievers, Stephen P. Cape, David McAdams, J'aime Manion, Pankaj Pathak
-
Publication number: 20130195913Abstract: The invention relates to live attenuated parvoviruses, their uses, vaccines comprising such live attenuated parvoviruses, as well as methods for their production.Type: ApplicationFiled: July 18, 2011Publication date: August 1, 2013Inventor: Norman Spibey
-
Publication number: 20130195892Abstract: The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.Type: ApplicationFiled: September 21, 2011Publication date: August 1, 2013Inventors: Martin Beer, Ilona Reimann, Patricia Koenig
-
Publication number: 20130149334Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.Type: ApplicationFiled: October 7, 2011Publication date: June 13, 2013Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
-
Patent number: 8460680Abstract: A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed.Type: GrantFiled: April 20, 2010Date of Patent: June 11, 2013Assignee: National Health Research InstitutesInventors: Yen-Hung Chow, Charles Dwo-Yuan Sia, Pele Choi-Sing Chong, Kuang-Nan Hsiao
-
Patent number: 8454972Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.Type: GrantFiled: January 20, 2011Date of Patent: June 4, 2013Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
-
Publication number: 20130129779Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.Type: ApplicationFiled: December 28, 2012Publication date: May 23, 2013Inventors: Paul Joseph Dominowski, Mark D. Goodyear, Michael John Huether
-
Patent number: 8445663Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.Type: GrantFiled: January 29, 2010Date of Patent: May 21, 2013Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Lars Frelin